OBJECTIVE: In vitro evidence suggests that basic fibroblast growth factor (bFGF) promotes tumor cell proliferation and angiogenesis. In this study, we evaluated the early and delayed effects of recombinant human bFGF on the early and late phases of in vivo, in situ tumorigenesis in rats.
Current research on fundamental brain tumor biology focuses on factors that promote or inhibit tumor growth. Basic fibroblast growth factor (bFGF) is a heparin-binding growth factor (2, 8, 13, 15, 41) that is mitogenic in vitro for various tissues of mesodermal and neuroectodermal origin (32) , including vascular endothelial cells and smooth muscle cells (9, 10) . In normal rats (5, 10, 13, 30) and rats with chronic forebrain ischemia (18, 28) , bFGF induces cerebral angiogenesis. bFGF has been found in the matrix surrounding proliferating blood vessels in gliomas (38) , and expression of vascular endothelial growth factor, which is closely related to bFGF, is 20-to 50-fold higher in high-grade malignant gliomas than in low-grade gliomas (42) . Clinical evidence suggests that brain tumor angiogenesis is associated with increased tumor cell proliferation and more aggressive tumor behavior (11) .
There is in vitro evidence that bFGF plays a role in the proliferation of neuronal and glial precursor cells (43) . In high-grade astrocytomas, the expression of fibroblast growth factor (FGF) has been found to be higher than in normal brain (39) . Moreover, some glioma cells and experimental glioma cell cultures bear high-affinity bFGF receptors (20) . Furthermore, recent studies show that FGF receptor gene expression is higher in glioblastoma than in non-neoplastic brain (25, 26) . These data suggest that bFGF plays an important role in determining the malignant potential of astrocytes.
In this study, we assessed the in vivo effects of bFGF on the early and late phases of tumorigenesis in rats exposed transplacentally toN-nitrosoethylurea (ENU). This widely used model yields brain tumors in 90% of offspring (7, 17) . Early neoplastic lesions appear in the white matter adjacent to the ventricles on postnatal (PN) Day 60 (35) ; histologically, these lesions consist of astrocytes, oligodendrocytes, and cells of uncertain origin (22) . Between 60 and 90 days, microtumors(300-500 µm in diameter) develop; these lesions have higher cellular density than do the early lesions and have proliferating centers consisting of densely packed cells with scanty cytoplasm. These findings are similar to those observed in human gliomas. The delivery system used for bFGF was stereotactic implantation of Gelfoam saturated with 60 µg of bFGF. The rats treated with bFGF showed a significant increase in the rate of tumor formation, compared with vehicle-treated control rats.
MATERIALS AND METHODS

Animals
Eighteen pregnant Sprague-Dawley rats were give a single intraperitoneal injection of ENU (80 mg/kg; Sigma Chemical Co., St. Louis, MO)(35) on Day 17 of pregnancy, to induce primary cerebral neoplasms in their offspring. In our pilot experiments, ENU induced brain tumors in 90% of the off-spring. Each pregnant female rat was caged separately. The rats were maintained on a 12-hour light/dark cycle and had free access to food and water. The pups were weaned at 4 weeks of age and separated by gender. The experimental protocol was approved by our institutional Animal Care and Use Committee, and the rats were monitored according to the guidelines of our Center for Laboratory Animal Science.
Preparation and administration of bFGF
The bFGF solution was prepared by diluting 1 ml of purified human recombinant bFGF (Amgen, Boulder, CO) in vehicle consisting of 1 ml of 0.9 N sodium chloride solution and 6.6 mg (150 units) of heparin, to stabilize the bFGF (14) . The final concentration of bFGF was 5µg/µl. This form of bFGF has been previously used in rats by others, without any immunological response by the host (12, 21) .
Rats were anesthetized with 3.5% chloral hydrate (10 ml/kg) supplemented with locally administered lidocaine and were placed in a stereotactic frame. The bregma was exposed under stereotactic guidance, a highspeed drill was used to make a burr hole in the calvarium, and a 20-gauge spinal needle containing 3 mm 3 of
Gelfoam saturated with bFGF (60 µg) was inserted into the right lateral ventricle (28) . The Gelfoam was implanted into the ventricle by passing the stylet of the spinal needle through the cannula. The coordinates for the intraventricular implant, mapped in relation to bregma, were -20 mm anteroposterior, 15 mm lateral, and-35 mm vertical (29) . The fate and distribution of bFGF administered in the brain have been reported in the literature and are characterized by exceptionally long local binding, because bFGF can be detected in the brain after 7 days (12, 19) .
Groups studied
To assess the effects of bFGF during different phases of tumorigenesis, rats were treated on PN Day 60 ("early treatment") or 90 ("late treatment"). To assess the early and delayed effects of bFGF, rats were killed 4 and 30 days, respectively, after treatment (Table 1) . Because the ENU-induced tumor model shows some heterogeneity among litters, each group consisted of more than one litter, and rats in each litter were randomly assigned to experimental and control groups.
TABLE 1. Experimental Groups
The control rats for each experimental group were age-matched, ENU-exposed rats treated with vehicle (n = 50). Additional control rats consisted of ENU-exposed untreated rats (n = 20) and sham-operated rats not exposed to ENU(n = 20).
Tissue preparation and histological and immunohistochemical analyses
On postimplant Day 4 or 30, rats were anesthetized with chloral hydrate(10 ml/kg) and transcardially perfused with a mixture of 4% buffered paraformaldehyde (pH 7.4) and 10% carbon black, to delineate blood vessels. The brains were postfixed with paraformaldehyde for 24 to 48 hours, embedded in paraffin, cut into 10-µm-thick sections, and stained with hematoxylin/eosin and Luxol blue/cresyl violet.
The tumor rate was quantified, in a double-blind fashion, by two investigators counting the number of brain tumors on coronal sections stained for glial fibrillary acidic protein (GFAP) (see below) and counterstained with cresyl violet, at each of the following four levels: bregma + 0.70, bregma -0.80, bregma -3.14, and bregma -4.80 (29) . ENU-induced tumors consist of mixed oligoastrocytomas and are easily recognizable, in hematoxylin/eosin-stained sections, as discrete areas of increased cellularity (4, 22) . The tumor rate was graded based on the total number of tumors, as follows: Grade I, 0 to 2 tumors; Grade II, 3 to 5 tumors; Grade III, >5 tumors. Angiogenesis within and adjacent to the tumors was graded semiquantitatively, as normal or increased, in the sections that were used to quantify the tumor rate.
Expression of GFAP was assessed on the sections that were used to quantify the tumor rate. GFAP expression was analyzed at the periphery of the tumor nodule (reactive astrocytes) and within the tumor nodule (tumoral astrocytes) (4, 22) . Brain sections were immunohistochemically stained for GFAP with the peroxidase/antiperoxidase technique (39) (DAKO kit; DAKO, Santa Barbara, CA). A custom-built videomicroscopy unit and its software (Signal Analytics Inc., Vienna, VA) were used to analyze the degree of astrocytic reaction, in the tumors and in areas adjacent to the implantation site, in GFAP-stained sections that were not counterstained. At each level, high-power fields (magnification, ×400) for each tumor were analyzed for GFAP expression, which was quantitated as the percentage of GFAP-positive cells in the region of interest.
Statistical analysis
The statistical significance of differences in the tumor rate between bFGF-treated rats and vehicle-treated control rats and between vehicle-treated rats and ENU-exposed untreated rats was analyzed with the [chi] 2 test for each group. The significance of differences in GFAP expression between bFGF-treated rats and vehicletreated control rats was analyzed with the unpaired t test.
RESULTS
Tumor types and location
The brain tumors induced by ENU were oligoastrocytomas characterized by high cellularity and disruption of the blood-brain barrier. The tumors were mainly located periventricularly, in the subcortical white matter, basal ganglia, and intraseptal nucleus (Fig. 1) . The tumor location did not differ in any group. 
Effects of bFGF on tumorigenesis
The tumor rate was significantly higher in rats treated with bFGF on PN Day 90 and examined 30 days later (Group IV) than in vehicle-treated control rats (P < 0.05) (Fig. 2) . In the other groups, there were no statistically significant differences in tumor rate between bFGF-treated rats and vehicle-treated control rats. No differences in tumor rate between ENU-exposed, vehicle-treated rats and ENU-exposed, untreated rats were found. Shamoperated rats not exposed to ENU had no tumors. FIGURE 2. Bar graph showing tumor rate grades in ENU-exposed rats treated with bFGF or vehicle on PN Day 60 and examined 30 days later (Group IV). The bFGF-treated rats had significantly more tumors than did vehicletreated control rats (P < 0.05).
Mitotic figures were seen in GFAP-positive cells in tumor nodules in 1 of 12 rats treated with bFGF on PN Day 60 and examined 4 days later (Group I) (Fig. 3) . No mitotic figures were observed in vehicle-treated control rats. 
Effects of bFGF on angiogenesis
Increased vascularity was seen in the tumor ipsilateral to the implant in 2 of 14 rats treated with bFGF on PN Day 60 and examined 4 days later (Group I) (Fig. 4) . Vascularity was not increased in vehicle-treated or untreated control rats. In the other groups, there were no differences in angiogenesis between bFGF-treated rats and control rats. 
Effects of bFGF on astrocytosis
In rats treated with bFGF on PN Day 60 or 90 and examined 30 days later(Groups III and IV), GFAP expression was significantly higher than in vehicle-treated control rats, both within the tumors and in areas adjacent to the intraventricular implant (Fig. 5) . FIGURE 5. Photomicrographs of coronal brain sections from ENU-exposed rats treated with vehicle (A) or bFGF(B) on PN Day 90 and examined 30 days later (Group IV). GFAP expression was increased in the bFGF-treated rat but not in the control rat.Arrowheads, sampled astrocytes. The sections was immunohistochemically stained for GFAP and were counterstained with cresyl violet. Bar, 40 µm.
DISCUSSION
In this study, bFGF increased the number of brain tumors induced in rats by transplacental exposure to ENU, and it subsequently increased intratumoral and periventricular expression of GFAP. To our knowledge, this is the first report in which exogenous bFGF has been shown to influence cerebral tumorigenesis in vivo.
Effects of bFGF on tumorigenesis
A possible role for the FGF polypeptides in oncogenesis is supported by the identification of oncogenes that encode proteins with 50% sequence homology with one of the seven FGF polypeptides (3, 6) . Furthermore, malignant glioma cell lines in culture have been shown to express high levels of bFGF messenger ribonucleic acid (40) . In vitro, transfection of glioma cells with antisense bFGF complementary deoxyribonucleic acid reduces levels of immunologically detectable bFGF and diminishes cellular growth. In contrast, transfection of glioma cell lines with bFGF complementary deoxyribonucleic acid in the sense orientation results in high levels of bFGF expression and increased tumor cell proliferation (31) . In our study, in vivo administration of bFGF significantly increased the number of experimentally induced brain tumors.
In vitro studies of glioma cells have provided evidence that bFGF plays an important role in promoting the malignant transformation of cultured astrocytes (1, 16, 23, 25) , by acting on tyrosine kinase-linked receptors (24, 33, 34) . Gross et al. (16) suggested that glioma cells express both growth factors and receptors. This double expression is the basis of autocrine stimulation that may promote uncontrolled growth of tumor cells (16, 44) . The acquisition of an unrelated autocrine loop involving bFGF may be one step along a multistep pathway of mutations or cellular alterations leading to neoplasia (36) . However, the time of acquisition of such an autocrine loop has not been fully defined. In our study, we found that bFGF exposure at PN
Effects of bFGF on angiogenesis
Angiogenesis is a normal pathophysiological response to many forms of injury, including trauma, infection, infarction, and tumor (10) . This response may be partially mediated by endogenous bFGF (5, 9, 10, 18, 21, 27, 30) . Solid tumors are thought to be angiogenesis dependent and secrete factors that promote endothelial cell proliferation; FGF has been found in higher concentrations in anaplastic astrocytomas than in normal brain (20, 23, 38, 40) . Furthermore, Stan et al. (37) showed inhibition of angiogenesis and tumor growth after treatment with an antibody against FGF, in an experimental brain tumor model. However, Morrison et al. (25, 26) recently demonstrated, in in vitro studies, that the higher FGF receptor gene(FGF1) messenger ribonucleic acid expression is limited to glioblastoma cells and does not occur in endothelial cells within the tumor. In our in vivo study, we showed that only 2 of 14 rats had increased vascularity ipsilateral to the tumor after exposure to exogenous bFGF at PN Day 60. This finding suggests that bFGF may increase angiogenesis only in the early phase of tumorigenesis. In later phases of tumorigenesis, bFGF increased the tumor rate, as well as GFAP expression and mitosis, but we did not observe any increase in angiogenesis. These data corroborate previous in vitro work (25, 26) and suggest that the main action of bFGF in tumorigenesis is its direct effect on astrocytes.
Effects of bFGF on astrocytosis and brain tumor cells
For tumors induced by transplacental exposure to ENU, some authors have demonstrated GFAP expression (4), whereas others have not (22) . There is debate regarding whether astrocytes with GFAP expression in these tumors are reactive or tumoral astrocytes. These GFAP-positive astrocytes could be malignant astrocytes or transitional tumor cells that express GFAP (4). In our study, bFGF increased GFAP expression in astrocytes in ENU -induced brain tumors, as well as in periventricular areas adjacent to the bFGF implant. In view of the presence of high-affinity bFGF receptors on glioma cells (20), we think that this increase in GFAP expression represents an independent effect of bFGF on glioma cells in vivo.
CONCLUSIONS
In vivo administration of bFGF increases the tumor rate in rats with ENU-induced brain tumors and causes increased expression of GFAP. In this experimental model, angiogenesis is seen rarely and only as an early effect. Thus, the primary effect of bFGF on tumorigenesis appears to be its delayed effect on astrocytes.
This study contributes to the growing body of evidence that primary brain tumors can eventually be treated by targeting bFGF and related growth factors. Anti-bFGF antibodies have been shown to inhibit angiogenesis and tumor growth in vitro (37) , and other factors, such as vascular endothelial growth factor, may add to the angiogenic potential of brain tumors. Potential therapies may include chemical or antibody blockade of the bFGF protein, inhibition of protein transcription, or receptor blockade. Such therapy may have a twofold effect, causing tumor shrinkage and devascularization as well as decreased tumor cell proliferation.
COMMENTS
This study by Segal et al. investigated an interesting observation regarding basic fibroblast growth factor (bFGF) and its possible mitogenic effects on N-nitrosoethylurea (ENU)-induced rat gliomas. The implication was that, after transplacental exposure to ENU and postnatal intraventricular treatment with bFGF at 90 days (with death 30 days later), more tumors were formed, compared with other treatment groups and control groups. Because this finding was coupled with the observation that angiogenesis was not as prominent as glial fibrillary acidic protein expression, a presumptive mitogenic effect on transformed astrocytes was hypothesized. Whether this leads to more histologically aggressive tumors, as the authors imply, is unknown. Glial fibrillary acidic protein expression may actually be decreased in glioblastomas, as opposed to pilocytic astrocytomas. The fibroblast growth factor receptor status of these ENU-induced tumors is unknown, which precludes definitive conclusions regarding targeting of growth factor receptors as a potential therapeutic modality.
Mitchel S. Berger
Seattle, Washington
The number of growth factors and growth factor receptors known to be expressed by brain tumor cells in vivo and in continues to expand, as increasing numbers of these factors and their receptors are examined. In this article, the authors demonstrated that a single dose of bFGF administered into the ventricle of rats that had been prenatally exposed to ENU led to increased numbers of tumors. This effect was observed only with rats that had undergone implantation of bFGF on postnatal Day 90 and were examined 30 days after bFGF implantation. Because this was a strictly observational study, no data were forthcoming concerning the mechanism of this effect. Additional work on the interaction of bFGF with transmembrane receptor tyrosine kinases and the effect of bFGF binding to these receptors in this model must be performed before any mechanistic data are obtained.
Corey Raffel
Rochester, Minnesota
In this study by Segal et al., the effects of bFGF on cerebral tumorigenesis in rats were determined. The authors used a model in which bFGF was implanted into the ventricle of ENU-exposed rats. The authors found that the rats treated with bFGF showed greater intratumoral angiogenesis than did control rats. I think that one of the most intriguing results in the article is the observation that bFGF may increase glial fibrillary acidic protein expression in astrocytic tumor cells. This observation provides an important pathway for studies of the effects of a growth factor such as bFGF on cells of the central nervous system. It is clear that we can no longer consider bFGF a stimulator of endothelial or vascular cells alone.
James T. Rutka
Toronto, Ontario, Canada
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